March 26, 2020 · Phase 2 readout
ABBV Phase 2 readout: a positive outcome, +8.7%
+8.7%AbbVie Inc. (ABBV) →
On March 26, 2020, Elsubrutinib — AbbVie Inc. (Systemic Lupus Erythematosus (SLE)) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +8.7% in the window around the event. It had already run -27.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$67.91
1d before
$73.83
Event day
$72.67
1d after
$76.19
5d after
Pre-catalyst setup
-27.7%
30-day run-up
9701%
30-day volatility